BR112016015997A2 - ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? - Google Patents

?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?

Info

Publication number
BR112016015997A2
BR112016015997A2 BR112016015997A BR112016015997A BR112016015997A2 BR 112016015997 A2 BR112016015997 A2 BR 112016015997A2 BR 112016015997 A BR112016015997 A BR 112016015997A BR 112016015997 A BR112016015997 A BR 112016015997A BR 112016015997 A2 BR112016015997 A2 BR 112016015997A2
Authority
BR
Brazil
Prior art keywords
hepe
methods
pharmaceutical compositions
understand
pulmonary disorders
Prior art date
Application number
BR112016015997A
Other languages
English (en)
Portuguese (pt)
Inventor
Climax John
Duffy Kenin
Manku Mehar
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of BR112016015997A2 publication Critical patent/BR112016015997A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112016015997A 2014-01-10 2015-01-12 ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? BR112016015997A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461926052P 2014-01-10 2014-01-10
PCT/US2015/011054 WO2015106215A2 (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Publications (1)

Publication Number Publication Date
BR112016015997A2 true BR112016015997A2 (pt) 2018-03-27

Family

ID=53520398

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015997A BR112016015997A2 (pt) 2014-01-10 2015-01-12 ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?

Country Status (15)

Country Link
US (2) US20150196521A1 (cg-RX-API-DMAC10.html)
EP (1) EP3091959A4 (cg-RX-API-DMAC10.html)
JP (2) JP2017505809A (cg-RX-API-DMAC10.html)
KR (1) KR20160132372A (cg-RX-API-DMAC10.html)
CN (1) CN106029051A (cg-RX-API-DMAC10.html)
AU (1) AU2015204531B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016015997A2 (cg-RX-API-DMAC10.html)
CA (1) CA2935986A1 (cg-RX-API-DMAC10.html)
IL (1) IL246623A0 (cg-RX-API-DMAC10.html)
MX (1) MX2016008953A (cg-RX-API-DMAC10.html)
PH (1) PH12016501371A1 (cg-RX-API-DMAC10.html)
RU (2) RU2019110980A (cg-RX-API-DMAC10.html)
SG (2) SG10202000496XA (cg-RX-API-DMAC10.html)
WO (1) WO2015106215A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201605492B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013259503B2 (en) 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
CN113893240A (zh) * 2015-01-16 2022-01-07 艾菲穆恩有限公司 包含15-hepe的组合物和其使用方法
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
MX379262B (es) * 2015-12-18 2025-03-10 Afimmune Ltd Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
CN100357244C (zh) * 2000-02-16 2007-12-26 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20060160095A1 (en) * 2002-12-13 2006-07-20 Eirx Therapeutics Limited Survivin
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
SI1863476T1 (sl) * 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
EP2607358A4 (en) * 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
AU2013259503B2 (en) * 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Also Published As

Publication number Publication date
CN106029051A (zh) 2016-10-12
AU2015204531A1 (en) 2016-08-18
EP3091959A2 (en) 2016-11-16
IL246623A0 (en) 2016-08-31
RU2016132762A3 (cg-RX-API-DMAC10.html) 2018-09-20
AU2015204531B2 (en) 2019-11-14
EP3091959A4 (en) 2017-09-20
MX2016008953A (es) 2017-02-02
ZA201605492B (en) 2018-11-28
RU2019110980A (ru) 2019-08-26
SG10202000496XA (en) 2020-03-30
WO2015106215A3 (en) 2016-02-18
US20160324820A1 (en) 2016-11-10
PH12016501371A1 (en) 2016-08-15
JP2020002150A (ja) 2020-01-09
JP2017505809A (ja) 2017-02-23
RU2016132762A (ru) 2018-02-16
US20150196521A1 (en) 2015-07-16
KR20160132372A (ko) 2016-11-18
SG11201605601UA (en) 2016-08-30
WO2015106215A2 (en) 2015-07-16
RU2685706C2 (ru) 2019-04-23
CA2935986A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112017006664A2 (pt) terapias de combinação
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX378273B (es) Compuestos activos hacia bromodominios.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
UA122341C2 (uk) Заміщені оксопіридинові похідні
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015027841A2 (pt) Método para umedecimento e/ou condicionamento do solo, concentrado da composição para tratamento do solo, e, uso de uma composição para tratamento do solo
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112017009315A2 (pt) composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
HK1248119A1 (zh) 有机氧化砷化合物和mtor抑制剂的药物组合
EA201501176A1 (ru) Замещенные бензоксазолы

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: AFIMMUNE LIMITED (IE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL